HMGB1 and ovarian cancer: Reducing NAC1 activity leads to lower HMGB1 levels and diminished autophagy, causing reduced growth and heightened apoptosis in ovarian cancer cells triggered by cisplatin, thereby increasing the cancer’s vulnerability to cisplatin (39).